1. Novartis to pay $678 to settle kickback claims — PhRMA sues Minnesota over insulin pricing law — Amgen Enbrel patents to be upheld through 2029 — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Do you have 7 minutes to fill out a quick survey about ordering food for work? You’ll be entered into a raffle to win a $100 Amazon.com gift card as a thank you for your time. click here
    Dismiss Notice

Praluent Sales Force on chopping block.... next up Repatha's

Discussion in 'Amgen' started by anonymous, Dec 13, 2019 at 2:51 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    It's only a matter of time before Amgen stops wasting money & other resources on Repatha. Way too many people selling it with the amount of salary they're paying out to reps. I mean most territories still have TWO reps (not including PCP rep) and now even a hospital rep. Are they serious?? Especially considering the terrible access in some places and now with the lack of competition from the other side. Time to rip the band-aid off. Best of luck to those reps that aren't the managers' favorites.
     

  2. Woody

    Woody new user

    Joined:
    Jul 5, 2019
    Messages:
    70
    Likes Received:
    0
    Yes, if you did NOT charge so much $$$$$ from the start, you may have had a decent chance of success. Not now! It is not the reps fault.
     
  3. anonymous

    anonymous Guest

    Thank God that I'm an "A" list rep!
     
  4. anonymous

    anonymous Guest

    Then develop your skills so that you can get a position that does not require a "mobile" marketer who excels at meal ordering.
     
  5. anonymous

    anonymous Guest

    Nah. Praluent rep here (hoping for severance because there’s no long term play on our end with Regeneron). The class is phenomenal, no one disputes that. Both were overpriced and managed care negotiations fkd themselves into the grave. Honestly, these drugs sold themselves when it came to efficacy and safety. Accessibility? Nail in the coffin. Guidelines? Another nail. You guys have a longer shelf life with Repatha because of your HF molecule coming to market. That space is no walk in the park either. Regeneron has zero CV pipeline outside of HoFH. Therefore, donzo. Incliseron may wipe the map with all PCSK9 asses but...not yet.
     
  6. anonymous

    anonymous Guest

    I’m trying to figure out do Amgen shills prefer over easy with Glide or a dab of Crisco?

    thanks
     
  7. anonymous

    anonymous Guest

    You're right. Anyone not in their fifties yet should definitely look into other industries. No doubt.
     
  8. anonymous

    anonymous Guest

    The HF drug won't need that many people selling it. One CV office based person and then the hospital rep. That's all they need but knowing BIG pharma... they'll over-hire for it.
     
  9. anonymous

    anonymous Guest

    Well?
     
  10. anonymous

    anonymous Guest

    So only the lawyers really won on the PCSK9 battle!!
     
  11. anonymous

    anonymous Guest

    Repatha should’ve been offloaded long ago. Complete failure on all fronts but it was a current SVPs launch. And so the business was protected for a long time.
     
  12. anonymous

    anonymous Guest

    Hey you fuckers. I'll return the favor of visiting and posting on your boards. Ex-praluent rep here. You piss ants are toast and you dont' even know it. Nobody needs your fucking asses. Now that the RAS's are gone, you wont be able to sell shit! That lawsuit bullshit. The price reduction bull fucking shit. Over sampling. Over spending on huge clinics lunches. Too many reps. What a fucking group. Yeah you beat us in reducing the team of RAS's, and we followed suit. Now we beat you to the punch and fired our praluent team. Guess who will follow our lead you fucking pricks? Thats right-you will all most likely lose your jobs. So go talk about you fucking 15% reduction in outcomes. Inclisirin is going to kick your fucking asses. Better yet, Esperion will kick your asses as well because payers will make providers use it before a PCSK9. Oh! but it doesn't have any outcomes yet! Precisely. You dont need outcomes anymore shits.

    I hope and can't wait for all you good for fucking nothing repatha reps to lose your jobs. you suck the asses right out of the clinics you call on. Ive got two fuckers in my territory who schedule 3-4 lunches a month with the same clinics and same practitioners in it. If it wasn't for your legal team, I mean sales team of RAS's,. and if it weren't for an endless supply of samples and lunch money, you fuckers wouldn't be able to sell jack shit. If i do get a job with Norvartis, I'm going to kick your fucking asses all over the place. Even if I don't, I'll be looking forward to reading that they own Amgen. Good thing you're in the pharma business where you dont have to actually sell. Any other industry and you would have been gone after about a year. So fuck off you bunch of ass licks.
     
  13. anonymous

    anonymous Guest

    Ok, keep us posted.
     
  14. anonymous

    anonymous Guest

    [​IMG]
     
  15. anonymous

    anonymous Guest

    you guys all suck.
     
  16. anonymous

    anonymous Guest

    OK Jen. Thx for the update.
     
  17. anonymous

    anonymous Guest

     
  18. anonymous

    anonymous Guest

    So true... so true! Repatha and Praluent simply can’t discount enough to compete with Novartis and Esperion.
     
  19. anonymous

    anonymous Guest

    [​IMG]
     
  20. anonymous

    anonymous Guest

    abort. abort... more and more Amgen managers jumping ship to join Esperion. Writing is all over the walls.